DE60027768T2 - Behandlung von metastatischer krankheit - Google Patents
Behandlung von metastatischer krankheit Download PDFInfo
- Publication number
- DE60027768T2 DE60027768T2 DE60027768T DE60027768T DE60027768T2 DE 60027768 T2 DE60027768 T2 DE 60027768T2 DE 60027768 T DE60027768 T DE 60027768T DE 60027768 T DE60027768 T DE 60027768T DE 60027768 T2 DE60027768 T2 DE 60027768T2
- Authority
- DE
- Germany
- Prior art keywords
- epha2
- cells
- metastatic
- use according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14925899P | 1999-08-17 | 1999-08-17 | |
| US149258P | 1999-08-17 | ||
| PCT/US2000/022670 WO2001012172A1 (en) | 1999-08-17 | 2000-08-17 | Treatment of metastatic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60027768D1 DE60027768D1 (de) | 2006-06-08 |
| DE60027768T2 true DE60027768T2 (de) | 2007-04-05 |
Family
ID=22529456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60027768T Revoked DE60027768T2 (de) | 1999-08-17 | 2000-08-17 | Behandlung von metastatischer krankheit |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP2289940A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2003516930A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE324877T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU6784400A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2380888A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60027768T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1242060T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2261230T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1242060E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001012172A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| DZ3332A1 (fr) | 2000-03-31 | 2001-10-11 | Purdue Research Foundation | Methode de traitement a l'aide de conjugues ligand-immunogene |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| NZ537458A (en) * | 2001-01-23 | 2007-02-23 | Primagen Holding B | Means and methods for treatment evaluation |
| EP1225233A3 (en) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
| EP1298221A1 (en) * | 2001-09-28 | 2003-04-02 | PrimaGen Holding B.V. | Means and methods for treatment evaluation |
| DE60234782D1 (de) * | 2001-09-28 | 2010-01-28 | Purdue Research Foundation | Behandlungsverfahren mit liganden-immunogenkonjugaten |
| AU2003215190A1 (en) * | 2002-02-15 | 2003-09-09 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
| EP1519956B1 (en) * | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| EP1575509B1 (en) * | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| EP1505999A4 (en) | 2002-05-23 | 2009-07-08 | Purdue Research Foundation | LOW-MOLECULAR PROTEIN-TYROSINE PHOSPHATASE (LMW-PTP) AS DIAGNOSTIC AND THERAPEUTIC TARGET |
| AU2004210463B2 (en) * | 2003-02-07 | 2009-07-16 | Ludwig Institute For Cancer Research Limited | Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
| AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| EP1617864A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL TROUBLESHOOTING |
| EP1618184A4 (en) * | 2003-04-11 | 2006-06-21 | Medimmune Inc | EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION |
| CA2525929A1 (en) | 2003-05-13 | 2004-11-25 | Chiron Corporation | Methods of modulating metastasis and skeletal related events resulting from metastases |
| WO2005016381A2 (en) * | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
| KR20060135671A (ko) * | 2003-11-20 | 2006-12-29 | 메디뮨 인코포레이티드 | EphA2 작동성 모노클로날 항체 및 이의 사용 방법 |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| AU2005277641A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| BRPI0607450A2 (pt) | 2005-02-04 | 2009-09-01 | Raven Biotechnologies Inc | anticorpos que se ligam a epha2 e métodos para sua utilização |
| WO2007092299A2 (en) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
| ZA200900545B (en) * | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| AU2007342333B2 (en) | 2006-09-12 | 2013-02-28 | Alphavax, Inc. | Alphavirus replicon particles encoding IL- 12 as immunological adjuvants |
| US20090022760A1 (en) | 2006-09-12 | 2009-01-22 | Alphavax | Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants |
| US20090047255A1 (en) | 2006-11-03 | 2009-02-19 | Alphavax, Inc. | Alphavirus and Alphavirus Replicon Particle Formulations and Methods |
| WO2009028639A1 (ja) * | 2007-08-30 | 2009-03-05 | Daiichi Sankyo Company, Limited | 抗epha2抗体 |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
| WO2018034332A1 (ja) * | 2016-08-19 | 2018-02-22 | 国立大学法人東京大学 | EphA2 N末端フラグメント抗体 |
| US20210268098A1 (en) | 2018-08-03 | 2021-09-02 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993003741A1 (en) | 1991-08-22 | 1993-03-04 | Becton, Dickinson & Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| CA2103323A1 (en) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
-
2000
- 2000-08-17 EP EP10010861A patent/EP2289940A3/en not_active Withdrawn
- 2000-08-17 ES ES00955687T patent/ES2261230T3/es not_active Expired - Lifetime
- 2000-08-17 AU AU67844/00A patent/AU6784400A/en not_active Abandoned
- 2000-08-17 DE DE60027768T patent/DE60027768T2/de not_active Revoked
- 2000-08-17 WO PCT/US2000/022670 patent/WO2001012172A1/en not_active Ceased
- 2000-08-17 CA CA002380888A patent/CA2380888A1/en not_active Abandoned
- 2000-08-17 JP JP2001516518A patent/JP2003516930A/ja active Pending
- 2000-08-17 DK DK00955687T patent/DK1242060T3/da active
- 2000-08-17 AT AT00955687T patent/ATE324877T1/de not_active IP Right Cessation
- 2000-08-17 EP EP00955687A patent/EP1242060B1/en not_active Revoked
- 2000-08-17 PT PT00955687T patent/PT1242060E/pt unknown
-
2007
- 2007-08-15 JP JP2007211840A patent/JP2007306938A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK1242060T3 (da) | 2006-08-21 |
| JP2007306938A (ja) | 2007-11-29 |
| PT1242060E (pt) | 2006-08-31 |
| EP1242060A1 (en) | 2002-09-25 |
| WO2001012172B1 (en) | 2001-08-16 |
| WO2001012172A1 (en) | 2001-02-22 |
| DE60027768D1 (de) | 2006-06-08 |
| EP1242060B1 (en) | 2006-05-03 |
| ATE324877T1 (de) | 2006-06-15 |
| EP2289940A3 (en) | 2011-09-21 |
| AU6784400A (en) | 2001-03-13 |
| CA2380888A1 (en) | 2001-02-22 |
| JP2003516930A (ja) | 2003-05-20 |
| EP1242060A4 (en) | 2003-09-24 |
| ES2261230T3 (es) | 2006-11-16 |
| EP2289940A2 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6927203B1 (en) | Treatment of metastatic disease | |
| EP1242060B1 (en) | Treatment of metastatic disease | |
| DE69735368T2 (de) | Behandlung und diagnose von krebs | |
| DE69518919T2 (de) | Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung | |
| DE60128208T2 (de) | Verfahren zum Behandeln von Krebs mit Anti-Neurotrophin-Mitteln | |
| Nakajima et al. | Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model | |
| JP5601836B2 (ja) | Tes7およびtes7に結合する抗体 | |
| DE68929384T2 (de) | Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor | |
| DE60038252T2 (de) | Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3 | |
| DE69631686T2 (de) | Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften | |
| DE69936780T2 (de) | Antikörper gegen eine lar-phosphatase untereinheit | |
| DE3852054T2 (de) | Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung. | |
| DE69431602T2 (de) | Monoklonale antikörper zur diagnose und behandlung von kolorektalkrebs | |
| DE69128543T2 (de) | Monoklonale antikörper der maus | |
| DE69534996T2 (de) | Monoklonaler antikörper gegen flt4-rezeptor-tyrosin-kinase und dessen verwendung zur diagnose und therapie | |
| DE60223688T2 (de) | Verfahren zur behandlung von multiplem myelom | |
| DE69911322T2 (de) | Monoklonaler antikörper der die oligosaccharide sialinsäure n-glycolierte galactose-glucose auf bösartige tumoren erkennt und zusammensetzungen die dieser enthalten | |
| JPH06501705A (ja) | 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療 | |
| DE69121555T2 (de) | Zell-spezifische enzymkonjugate, die toxisches cyanide aus cyanogenen vorläuferdrogen an zielzellen freisetzen | |
| CN101279093A (zh) | 癌症调节抗体 | |
| DE60109359T2 (de) | Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten | |
| DE212011100195U1 (de) | Antikörper, der das Tumorwachstum stoppt oder verzögert (Varianten) | |
| EP1399186B1 (de) | Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein | |
| CN107106669A (zh) | 用于治疗过度表达HIF‑1α的癌症的组合物和方法 | |
| AU2006202023B2 (en) | Treatment of metastatic disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |